- Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
- SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
- Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
- Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
- Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
- Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
- Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
More ▼
Key statistics
As of last trade, Apellis Pharmaceuticals Inc (APLS:NSQ) traded at 36.18, 82.45% above the 52 week low of 19.83 set on Aug 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.75 |
---|---|
High | 36.38 |
Low | 35.10 |
Bid | 36.14 |
Offer | 36.18 |
Previous close | 35.41 |
Average volume | 1.76m |
---|---|
Shares outstanding | 121.37m |
Free float | 103.98m |
P/E (TTM) | -- |
Market cap | 4.30bn USD |
EPS (TTM) | -3.46 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:25 BST.
More ▼